Last Updated : May 17, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort ascending | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Adcetris | brentuximab vedotin | Hodgkin lymphoma | Withdrawn | |||
Winlevi | clascoterone | Acne vulgaris | Withdrawn | |||
Prevymis | letermovir | Cytomegalovirus infection (CMV), prophylaxis | Withdrawn | |||
Myalepta | metreleptin | Leptin deficiency in lipodystrophy | Active | |||
Adtralza | tralokinumab | atopic dermatitis (AD) | Active | |||
TBC | sotatercept | Pulmonary arterial hypertension (WHO group 1) | Active | |||
TBC | eplontersen | Polyneuropathy in hereditary transthyretin-mediated amyloidosis | Active | |||
Libtayo | cemiplimab | Locally advanced or metastatic NSCLC (first line) | Active | |||
Doptelet | avatrombopag | Chronic immune thrombocytopenia (ITP) | Active | |||
Epkinly | epcoritamab | Relapsed or refractory diffuse large B-cell lymphoma | Active |